Clinical Trials

60 enrolled

Pathologic Complete Response, Carcinoma, Non-Small-Cell Lung

NCT04083599 2026-06-02

GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors

DermatologicGastrointestinalHead & NeckThoracic

350 enrolled

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Melanoma, Colorectal Neoplasms

NCT05739981 2026-06-02

MRD

30 enrolled

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT01386385 2026-05-26

Veliparib With or Without Radiation Therapy, Carboplatin, and Paclitaxel in Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery

53 enrolled 21 charts

Adenocarcinoma of Lung, Adenocarcinoma, Bronchiolo-Alveolar

NCT05319730 2026-05-26

MK-3475-06B

230 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms

NCT06843447 2026-05-26

MK-5909-003

460 enrolled

Ovarian Cancer Recurrent

NCT04053205 2026-05-22

A Study of Gentuximab + Paclitaxel in Patients With Advanced Gastric or Gastroesophageal Junction Cancer

Phase 1/2 Completed

76 enrolled

Advanced Gastric or Gastroesophageal Junction Cancer

NCT04165070 2026-05-18

MK-3475-01A

450 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung

NCT07042802 2026-05-18

A Phase Ib/Ⅱ Clinical Trial of LBL-024 Combined With Paclitaxel in Patients With Platinum-resistant Ovarian Cancer

110 enrolled

Ovarian Neoplasms

NCT05019716 2026-05-13

Testing the Safety and Efficacy of the Addition of a New Anti-cancer Drug, ZEN003694, to Chemotherapy Treatment (Cisplatin and Etoposide or Carboplatin and Paclitaxel) for Adult and Pediatric Patients (12-17 Years) With NUT Carcinoma

36 enrolled

Advanced NUT Carcinoma

NCT06445972 2026-05-12

MK-3475-06D

210 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Neoplasms

NCT06474455 2026-05-11

A Phase IB/II Clinical Study of SHR-9839 for Injection Combined With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors

156 enrolled

Other solid neoplasm

Advanced Solid Tumors

NCT04331067 2026-05-06

Neoadjuvant Nivolumab and Chemotherapy in Patients With Localized Triple-negative Breast Cancer

15 enrolled 12 charts

Triple Negative Breast Neoplasms

NCT03393884 2026-05-04

OVATION 2

130 enrolled

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms

NCT06996782 2026-05-01

ALTAIR

152 enrolled

Carcinoma, Non-Small-Cell Lung

NCT02734290 2026-04-24

Standard of Care Chemotherapy Plus Pembrolizumab for Breast Cancer

29 enrolled 12 charts

Breast Neoplasms, Neoplasm Metastasis, Triple Negative Breast Neoplasms

NCT03742102 2026-04-24

BEGONIA

243 enrolled 13 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05108870 2026-04-24

TheraT® Vectors (Vaccines) Combined With Chemotherapy to Treat HPV16 Head and Neck Cancers

35 enrolled

Head & Neck

Head and Neck Neoplasms

NCT01980277 2026-04-21

TAKTIC

Phase 1/2 Terminated

68 enrolled

Breast Neoplasms

NCT06741644 2026-04-15

A Phase I/II Study of CS2009 in Participants With Advanced Solid Tumors

660 enrolled

Other solid neoplasm

Advanced Solid Tumors

NCT04938583 2026-04-06

Oregovomab in Combination With Bevacizumab Plus Chemo in BRCA Wild Type Platinum Sensitive Recurrent Ovarian Cancer

54 enrolled

Ovarian Neoplasms

NCT02077881 2026-04-03

Study of IDO Inhibitor in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Cancer

Phase 1/2 Completed

157 enrolled 18 charts

Adenocarcinoma, Neoplasm Metastasis, Neoplasms, Pancreatic Neoplasms

NCT03568422 2026-03-27

CFI-402257 in Combination With Paclitaxel in Patients With Advanced/Metastatic HER2-Negative Breast Cancer

37 enrolled 14 charts

Breast Neoplasms

NCT04008797 2026-03-24

A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor

GastrointestinalGynecologic

301 enrolled

Carcinoma, Hepatocellular, Liver Neoplasms, Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

NCT07472647 2026-03-16

SYS6090 Combination Therapy in Advanced Lung Cancer

Phase 1/2 Not yet recruiting

596 enrolled